T6331

Allitinib tosylate (AST-1306) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, respectively.

α-Glucosidase-IN-6 is a competitive inhibitor of α-glucosidase (IC50: 5.69 μM) and exhibits potential for anti-diabetic studies.

PfPKG-IN-1, an imidazole-based inhibitor, targets the Plasmodium falciparum cyclic guanosine monophosphate-dependent protein kinase (PfPKG).

ABT-639 hydrochloride is a selective, novel T-type Ca2+ channel blocker.

Antifungal agent 31 is an orally active, triazole antifungal agent possessing a pyrrolizinone scaffold that exhibits some antifungal activity against Candida and filamentous fungi.Antifungal agent 31 significantly reduced mortality and renal fungal burden in two mouse models of lethal systemic infection.

IRAK4-IN-19 is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) with an IC50 of 4.3 nM. It inhibits LPS-induced IL23 production in THP and DC cells and suppresses arthritis development in arthritic model rats. IRAK4-IN-19 can be used to study arthritic diseases.

BGC-20-1531 (PGN 1531) free base is a selective, potent prostaglandin EP4 receptor antagonist (pKB: 7.6) with potential applications in migraine research.

ATM Inhibitor -4 is a selective and potent ATM inhibitor (IC50: 0.32 nM) that strongly inhibits the activity of the PI3K kinase family and exhibits good metabolic stability. ATM Inhibitor -4 completely inhibits mTOR at 1 μM.

CFI-400437 is an ATP-competitive PLK4 inhibitor (IC50: 0.6 nM) and is an indolequinone derivative.

Antitubercular agent-32 is a Benzothiazinone derivative that inhibits Mycobacterium tuberculosis and exhibits good metabolic stability and water solubility. Antitubercular agent-32 can act on decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1, IC50: 3.9 μM) and exhibits antitubercular effects.